I now have enough data to write a strong, well-informed options note. Key signals:
Options traders moved fast on Tuesday's headlines. Three catalyst-driven names stand out, with put/call dynamics shifting sharply across pharma, fast food, and semiconductors.
BMY drew call interest after announcing a $15.2 billion deal with Hengrui Pharma. The pact covers 13 oncology and immunology programs. Bristol-Myers Squibb's RSI sits at 40 — still oversold. That combination of deep-value positioning and a blockbuster deal makes near-term call setups attractive. Analysts see 12.75% upside from current levels.
WEN is drawing speculative call flow after reports that Nelson Peltz is raising funds for a go-private bid. The stock carries a short score of 75 and days-to-cover of 6.5. That is a loaded spring. A confirmed bid could trigger a violent short squeeze. Options expiries run through June 26, giving traders several windows to play the deal timeline.
The semiconductor complex remains the week's biggest options battleground. SMH short utilization hit 94% — a 52-week high — even as the ETF has surged 32% in a month. Shorts are trapped. Options flow in MU (Micron) is also aggressive: the RSI stands at 83.77 and the stock is up 161% year-to-date. Traders are using near-term calls to chase semiconductor momentum.
On the bearish side, META posted a 0% positive options bet ratio over the past week. EU regulators are threatening minimum age limits for social media. That regulatory cloud is pushing put buyers in. MSFT remains down 14% year-to-date despite a reported $97 billion OpenAI savings deal. Its options expiry ladder runs dense through July, with traders watching whether the AI narrative reignites upward momentum.
This article is for informational purposes and does not constitute financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
